Bloomberg Pfizer Inc, maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion. Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said in a statement. The price represents a 118% premium to the stock’s 60-day weighted ...
Read More »